The earnings call reflected a positive sentiment, with significant achievements such as the early FDA approval and successful commercial launch of AVMAPKI FAKZYNJA CO-PACK. These positive developments were partially offset by increased R&D expenses and net loss. However, the highlights significantly outweigh the lowlights, indicating strong momentum and future potential.

Company Guidance

During the Verastem Oncology second quarter 2025 financial results call, the company's leadership provided comprehensive guidance on their recent FDA approval and commercial launch of the AVMAPKI FAKZYNJA CO-PACK for KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC). They reported $2.1 million in net product revenue within the first six weeks of the launch, highlighting the strong early traction and operational excellence demonstrated by the quick market entry, with product availability at designated specialty pharmacies within five days of approval. The launch strategy focused on engaging healthcare providers, supporting patients, and ensuring seamless access, with coverage from major insurers representing over 80% of U.S. lives. The company reinforced its commitment to educational efforts and patient advocacy, aiming to make the AVMAPKI FAKZYNJA CO-PACK the new standard of care. Financially, Verastem ended the quarter with $164.3 million in cash and investments, projecting a cash runway into the second half of 2026, backed by a strong balance sheet and successful commercial activities.

FDA Approval of AVMAPKI FAKZYNJA CO-PACK

Achieved FDA approval for AVMAPKI FAKZYNJA CO-PACK for KRAS-mutated recurrent LGSOC nearly 2 months ahead of schedule. This marks the first-ever truly novel/novel drug combination approved in oncology.

Successful Commercial Launch

Generated $2.1 million in net product revenue within the first 6 weeks of launch, indicating strong early traction and operational excellence.

Broad Insurance Coverage

Secured coverage from major insurers in the U.S., including the three largest PBMs, representing over 80% of lives.

Strengthened Financial Position

Completed a $75 million private placement, ending the quarter with $164.3 million in cash, cash equivalents, and investments.

Expansion of Distribution Network

Entered into multiple agreements with specialty distributors and oncology group purchasing organizations.

Verastem (VSTM) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

VSTM Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 30, 2025	2025 (Q3)	-0.62 / -	-0.6	―	―	―
Aug 07, 2025	2025 (Q2)	-0.73 / -0.39	-0.31	-25.81% (-0.08)	―
May 13, 2025	2025 (Q1)	-0.70 / -0.96	-1.26	23.81% (+0.30)	―	―
Mar 20, 2025	2024 (Q4)	-0.83 / -1.33	-1.02	-30.39% (-0.31)	―	―
Nov 06, 2024	2024 (Q3)	-0.74 / -0.60	-0.75	20.00% (+0.15)	―	―
Aug 08, 2024	2024 (Q2)	-0.96 / -0.31	-1.37	77.37% (+1.06)	―	―
May 09, 2024	2024 (Q1)	-1.03 / -1.26	-0.96	-31.25% (-0.30)	―	―
Mar 14, 2024	2023 (Q4)	-0.61 / -1.02	-0.96	-6.25% (-0.06)	―	―
Nov 08, 2023	2023 (Q3)	-0.84 / -0.75	-1.08	30.56% (+0.33)	―	―
Aug 08, 2023	2023 (Q2)	-1.04 / -1.37	-1.44	4.86% (+0.07)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

VSTM Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 07, 2025	$5.62	$6.74	+19.93%
May 13, 2025	$7.46	$7.13	-4.42%
Mar 20, 2025	$6.82	$6.65	-2.49%
Nov 06, 2024	$3.87	$3.60	-6.98%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Verastem (VSTM) report earnings?

Verastem (VSTM) is schdueled to report earning on Oct 30, 2025, After Close (Confirmed).

What is Verastem (VSTM) earnings time?

Verastem (VSTM) earnings time is at Oct 30, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is VSTM EPS forecast?

VSTM EPS forecast for the fiscal quarter 2025 (Q3) is -0.62.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing